Healthcare
0
Private healthcare the ‘ new normal’ in the UK? – Healthcare Economist
0

Perhaps so, according to the health policy editor of the guardian. he writes that As the NHS weakens, private health insurance is becoming a more ...

0
PREFER recommendations for patient preference studies – Healthcare Economist
0

Patient preferences should be the most important part of healthcare decision making. However, third parties often make decisions for patients. Doctors ...

0
A primer on formularies – Healthcare Economist
0

Hydery and Reddy (2024) provides a good introduction to medication formularies. Below is a quick overview. What is ...

0
Good practices for incorporating family and caregiver spillovers into health economic evaluations – Healthcare Economist
0

Diseases not only affect patients, but often also affect caregivers and family members. However, most economic analyzes ...

0
Are providers ready for biosimilars? – Healthcare Economist
0

Perhaps more education is needed. This is the conclusion of an article by Giovatto et al. (2024). The authors ...

0
Long term care spending around the world – Healthcare Economist
0

A great article by Gruber et al. 2023 analyzes the evolution of long-term care in ten countries: Canada, Denmark, ...

0
How COVID-19 could impact clinical trial results and what to do about it – Healthcare Economist
0

an article from Meyer et al. (2020) has a good summary of the potential mechanisms through which the presence of ...

0
55% of US Rural Hospitals Are No Longer Offer Birthing Services – Healthcare Economist
0

That is according to a article in JAMA based on report from the Center for Healthcare Quality and Payment Reform. The report states: More than half ...

0
Hartford HealthCare Opens Center for AI Innovation
0

Connecticut-based Hartford HealthCare has unveiled a Center for AI Innovation in Healthcare. The health system has a wide scope. It includes two tertiary ...

0
How will Medicaid pay for cell and gene therapies? – Healthcare Economist
0

One approach that CMS has is Access model to cell and gene therapy (CGT). Under the CGT Access Model, CMS (at the federal level) will negotiate ...

Tools4BLS
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart